The MRSA drug market will increase from $631m in 2009 to $752m in 2019 in the US, France, Germany, Italy, Spain, the UK and Japan, according to a report by Decision Resources.

It is expected that market growth will be driven by the uptake of several emerging agents, including Forest / AstraZeneca / Takeda’s ceftaroline and Trius Therapeutics’ torezolid, a second-generation oxazolidinone.

Ceftaroline recently received US Food and Drug Administration approval for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, while torezolid entered its first Phase III trial in August 2010.

These two agents alone are expected to capture more than one-third of the overall MRSA market in 2019.

The MRSA pipeline also contains several therapies being developed in intravenous and oral formulations, indicating developer recognition for the need for new oral MRSA therapies in hospital and community settings.